Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Truist Financial in a note issued to investors on Monday, Benzinga reports. They currently have a $42.00 price target on the biopharmaceutical company’s stock. Truist Financial’s price target would suggest a potential upside of 42.23% from the company’s previous close.
Several other equities analysts have also weighed in on the company. StockNews.com assumed coverage on Pfizer in a report on Thursday, October 5th. They set a “hold” rating for the company. Barclays cut their price target on Pfizer from $35.00 to $34.00 and set an “equal weight” rating for the company in a report on Wednesday, November 1st. Wells Fargo & Company cut their price target on Pfizer from $39.00 to $35.00 and set an “equal weight” rating for the company in a report on Monday, October 16th. TheStreet lowered Pfizer from a “b-” rating to a “c+” rating in a report on Monday, September 25th. Finally, Citigroup cut their price target on Pfizer from $42.00 to $35.00 and set a “neutral” rating for the company in a report on Monday, October 16th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $42.50.
Pfizer Stock Up 2.1 %
Shares of Pfizer stock traded up $0.62 on Monday, hitting $29.53. The company had a trading volume of 13,275,472 shares, compared to its average volume of 25,843,480. The stock has a market capitalization of $166.74 billion, a price-to-earnings ratio of 16.14, a P/E/G ratio of 1.87 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.38. The stock has a 50 day moving average of $31.24 and a 200-day moving average of $34.69. Pfizer has a 1 year low of $28.30 and a 1 year high of $54.93.
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.15. The company had revenue of $13.23 billion during the quarter, compared to analyst estimates of $13.77 billion. Pfizer had a return on equity of 16.72% and a net margin of 15.30%. As a group, sell-side analysts forecast that Pfizer will post 1.54 earnings per share for the current year.
Institutional Trading of Pfizer
Several large investors have recently modified their holdings of PFE. Quinn Opportunity Partners LLC bought a new stake in Pfizer during the 2nd quarter valued at approximately $10,304,000. Fifth Third Wealth Advisors LLC bought a new stake in Pfizer during the 2nd quarter valued at approximately $220,000. Atlas Wealth Partners LLC bought a new stake in Pfizer during the 2nd quarter valued at approximately $273,000. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new stake in Pfizer during the 2nd quarter valued at approximately $2,721,000. Finally, Kahn Brothers Group Inc. boosted its position in Pfizer by 3.5% during the 2nd quarter. Kahn Brothers Group Inc. now owns 1,066,091 shares of the biopharmaceutical company’s stock valued at $39,105,000 after acquiring an additional 36,429 shares in the last quarter. 68.05% of the stock is owned by institutional investors.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Pfizer wasn’t on the list.
While Pfizer currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Which stocks are likely to thrive in today’s challenging market? Click the link below and we’ll send you MarketBeat’s list of ten stocks that will drive in any economic environment.
Source: marketbeat.com
